COMPARING ROUTES OF KETAMINE ADMINISTRATION IN TREATMENT-RESISTANT DEPRESSION: EFFICACY, SAFETY, AND OPTIMIZATION OF DOSING STRATEGIES
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5567Keywords:
Treatment-Resistant Depression, Ketamine, Administration Routes, Acute, Maintenance, NeuroplasticityAbstract
Background: Treatment-resistant depression (TRD) is associated with substantial functional impairment, suicide risk, and health-care costs. Ketamine and its S-enantiomer, esketamine, have emerged as rapid-acting glutamatergic treatment options for TRD.
Aim: This review aims to synthesize current evidence on the different ketamine administration routes for TRD, with a focus on acute and maintenance efficacy, dosing strategies, safety, infrastructure needs, and positioning within stepped-care algorithms.
Methods: A narrative review of randomized controlled trials, meta-analyses, systematic reviews, and long-term open-label studies was performed. Outcomes were grouped by route and examined for (1) antidepressant response, (2) adverse-event profile, (3) required clinical resources, and (4) integration with other treatments such as electroconvulsive therapy and psychotherapy.
Results: Ketamine and esketamine can be administered via intravenous (IV), intranasal (IN), oral, subcutaneous (SC), and intramuscular (IM) routes. IV racemic ketamine shows the strongest and fastest antidepressant effect but demands infusion-suite equipment and monitoring for transient hypertension and dissociation. FDA-approved IN esketamine offers robust long-term data but requires administration under supervised in-clinic administration and blood pressure monitoring. According to the reviewed studies, IV and IN routes remain the best-supported options for achieving a rapid response. Oral, sublingual and extended-release formulations provide easier access and lower cost, but have reduced bioavailability, modest effect sizes, and higher diversion risk. These routes of administration may be useful for maintenance treatment in resource-constrained settings. SC and IM injections achieve ~90 % bioavailability with minimal infrastructure, yet evidence is limited to small series.
Conclusion: The optimal ketamine route is context-dependent, and requires balancing efficacy, safety, cost, and health-system capacity. Future research should include direct comparative trials and extended safety monitoring to better define the long-term efficacy, tolerability, and optimal clinical use of different ketamine administration routes.
References
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., Ly-Uson, J. T., Mansur, R. B., McAllister-Williams, R. H., Murrough, J. W., Nemeroff, C. B., Nierenberg, A. A., Rosenblat, J. D., Sanacora, G., Schatzberg, A. F., & Shelton, R. C. (2023). Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions. World Psychiatry, 22(3), 394–412. https://doi.org/10.1002/wps.21120
Glue, P., Loo, C., Fam, J., Lane, H.-Y., Young, A. H., & Surman, P. (2024). Extended-release ketamine tablets for treatment-resistant depression: A randomized placebo-controlled phase 2 trial. Nature Medicine, 30, 1–6. https://doi.org/10.1038/s41591-024-03063-x
Shiroma, P. R., Thuras, P., Wels, J., Albott, C. S., Erbes, C., Tye, S., & Lim, K. O. (2020). A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs. single subanesthetic ketamine for treatment-resistant depression. Translational Psychiatry, 10(1), 1–9. https://doi.org/10.1038/s41398-020-00897-0
Vestring, S., Galuba, V., Kern, E., Voita, S., Berens, F., Nasiri, D., Domschke, K., & Normann, C. (2024). Ketamine in multiple treatment-resistant depressed inpatients: A naturalistic cohort study. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.01.165
Dwyer, J. B., Landeros-Weisenberger, A., Johnson, J. A., Londono Tobon, A., Flores, J. M., Nasir, M., Couloures, K., Sanacora, G., & Bloch, M. H. (2021). Efficacy of intravenous ketamine in adolescent treatment-resistant depression: A randomized midazolam-controlled trial. American Journal of Psychiatry, 178(4), 352–362. https://doi.org/10.1176/appi.ajp.2020.20010018
Ionescu, D. F., Bentley, K. H., Eikermann, M., Taylor, N., Akeju, O., Swee, M. B., Pavone, K. J., Petrie, S. R., Dording, C., Mischoulon, D., Alpert, J. E., Brown, E. N., Baer, L., Nock, M. K., Fava, M., & Cusin, C. (2019). Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double-blind, placebo-controlled trial. Journal of Affective Disorders, 243, 516–524. https://doi.org/10.1016/j.jad.2018.09.037
Marcantoni, W. S., Akoumba, B. S., Wassef, M., Mayrand, J., Lai, H., Richard-Devantoy, S., & Beauchamp, S. (2020). A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment-resistant depression: January 2009–January 2019. Journal of Affective Disorders, 277, 831–841. https://doi.org/10.1016/j.jad.2020.09.007
Swainson, J., Klassen, L. J., Brennan, S., Chokka, P., Katzman, M. A., Tanguay, R. L., & Khullar, A. (2022). Non-parenteral ketamine for depression: A practical discussion on addiction potential and recommendations for judicious prescribing. CNS Drugs. https://doi.org/10.1007/s40263-022-00897-2
Zaki, N., Chen, L., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Popova, V., & Fu, D.-J. (2023). Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: Interim results of the SUSTAIN-3 study. Neuropsychopharmacology, 48(8). https://doi.org/10.1038/s41386-023-01577-5
Anand, A., Mathew, S. J., Sanacora, G., Murrough, J. W., Goes, F. S., Altinay, M., Aloysi, A. S., Asghar-Ali, A. A., Barnett, B. S., Chang, L. C., Collins, K. A., Costi, S., Iqbal, S., Jha, M. K., Krishnan, K., Malone, D. A., Nikayin, S., Nissen, S. E., Ostroff, R. B., & Reti, I. M. (2023). Ketamine versus ECT for nonpsychotic treatment-resistant major depression. The New England Journal of Medicine, 388(25). https://doi.org/10.1056/nejmoa2302399
Al-Garni, A. M., Vazquez, G., Alotibi, T., Hernandorena, C., & Knyahnytska, Y. (2026). Efficacy and safety of ketamine maintenance therapy in treatment-resistant depression: A systematic review of treatment protocols and clinical outcomes. Journal of Affective Disorders, 394, 120475. https://doi.org/10.1016/j.jad.2025.120475
Seshadri, A., Prokop, L. J., & Singh, B. (2024). Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for major depression: A systematic review and meta-analysis. Journal of Affective Disorders, 356, 379–384. https://doi.org/10.1016/j.jad.2024.03.137
Phillips, J. L., Norris, S., Talbot, J., Birmingham, M., Hatchard, T., Ortiz, A., Owoeye, O., Batten, L. A., & Blier, P. (2020). Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: A randomized controlled trial. FOCUS, 18(2), 236–243. https://doi.org/10.1176/appi.focus.18206
Kendirlioğlu, B. K., Özmen, M., Uluçay, S., Bayrak, T., Erturan, E. S., Salkım, Ö., Büyüksandalyacı Tunç, A. E., Arat Çelik, H. E., & Küçükgöncü, S. (2025). Combination of ketamine and electroconvulsive therapy in treatment-resistant depression. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.04.017
Sakopoulos, S., & Todman, M. (2025). The effects of psychotherapy on single and repeated ketamine infusion(s) therapy for treatment-resistant depression: The convergence of molecular and psychological treatment. International Journal of Molecular Sciences, 26(14), 6673. https://doi.org/10.3390/ijms26146673
Phillips, J. L., Norris, S., Talbot, J., Hatchard, T., Ortiz, A., Birmingham, M., Owoeye, O., Batten, L. A., & Blier, P. (2019). Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology, 45(4). https://doi.org/10.1038/s41386-019-0570-x
Smith-Apeldoorn, S. Y., Veraart, J. K., Spijker, J., Kamphuis, J., & Schoevers, R. A. (2022). Maintenance ketamine treatment for depression: A systematic review of efficacy, safety, and tolerability. The Lancet Psychiatry, 9(11), 907–921. https://doi.org/10.1016/S2215-0366(22)00317-0
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., Iosifescu, D. V., Lopez Jaramillo, C., Kasper, S., Kratiuk, K., Lee, J. G., Lee, Y., Lui, L. M. W., Mansur, R. B., Papakostas, G. I., & Subramaniapillai, M. (2021). Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. American Journal of Psychiatry, 178(5), appi.ajp.2020.20081251. https://doi.org/10.1176/appi.ajp.2020.20081251
Fiorillo, A., Demyttenaere, K., Martiadis, V., & Martinotti, G. (2025). Treatment-resistant depression (TRD): Epidemiology, clinic, burden and treatment. Frontiers in Psychiatry, 16, 1588902. https://doi.org/10.3389/fpsyt.2025.1588902
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Irmina Grygutis, Oskar Mikołajczyk, Kornelia Julia Fimiarz, Urszula Jarzęcka, Kinga Łysak, Sonia Pawełkiewicz, Kamil Wójcik, Aleksandra Serafin, Karolina Baran, Maja Podolak
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
